CLINICAL TRIALS The silent minority-unpublished data on cancer care

被引：3

作者：

Hayes, Daniel F. ^{[1
]}

机构：

[1] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA

来源：

NATURE REVIEWS CLINICAL ONCOLOGY | 2011年 / 8卷 / 11期

关键词：

HER2-POSITIVE BREAST-CANCER; ADJUVANT CHEMOTHERAPY; TRASTUZUMAB;

D O I：

10.1038/nrclinonc.2011.148

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

From 1989 to 2003, 709 phase III trials evaluating systemic cancer treatment were presented at ASCO meetings. Tam and collaborators have now reported that 9% of these trials were never published, and 13% were published after a 5-year delay. More than half of these studies would have had clinical impact if published promptly. © 2011 Macmillan Publishers Limited. All rights reserved.

引用

页码：631 / 632

页数：2

共 10 条

[1] Biomarker studies: a call for a comprehensive biomarker study registry [J].

Andre, Fabrice ;

McShane, Lisa M. ;

Michiels, Stefan ;

Ransohoff, David F. ;

Altman, Douglas G. ;

Reis-Filho, Jorge S. ;

Hayes, Daniel F. ;

Pusztai, Lajos .

NATURE REVIEWS CLINICAL ONCOLOGY, 2011, 8 (03) :171-176

[2]

[Anonymous], PATTERNS CARE MED ON

[3]

Early Breast Cancer Trialists' Collaborative Group (EBCTCG), 2005, LANCET, V365, P1687, DOI [10.1016/S0140-6736(05)66544-0, DOI 10.1016/S0140-6736(05)66544-0]

[4] Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer [J].

Joensuu, H ;

Kellokumpu-Lehtinen, P ;

Bono, P ;

Alanko, T ;

Kataja, V ;

Asola, R ;

Utriainen, T ;

Kokko, R ;

Hemminki, A ;

Tarkkanen, M ;

Turpeenniemi-Hujanen, T ;

Jyrkkiö, S ;

Flander, M ;

Helle, L ;

Ingalsuo, S ;

Johansson, K ;

Jääskeläinen, A ;

Pajunen, M ;

Rauhala, M ;

Kaleva-Kerola, J ;

Salminen, T ;

Leinonen, M ;

Elomaa, I ;

Isola, J .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (08) :809-820

[5]

Lefebvre C., 2008, COCHRANE HDB SYSTEMA

[6]

Love N., 2005, PATTERNS CARE MED ON, V1

[7] Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer [J].

Piccart-Gebhart, MJ ;

Procter, M ;

Leyland-Jones, B ;

Goldhirsch, A ;

Untch, M ;

Smith, I ;

Gianni, L ;

Baselga, J ;

Bell, R ;

Jackisch, C ;

Cameron, D ;

Dowsett, M ;

Barrios, CH ;

Steger, G ;

Huang, CS ;

Andersson, M ;

Inbar, M ;

Lichinitser, M ;

Láng, I ;

Nitz, U ;

Iwata, H ;

Thomssen, C ;

Lohrisch, C ;

Suter, TM ;

Ruschoff, J ;

Süto, T ;

Greatorex, V ;

Ward, C ;

Straehle, C ;

McFadden, E ;

Dolci, MS ;

Gelber, RD .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16) :1659-1672

[8] Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer [J].

Romond, EH ;

Perez, EA ;

Bryant, J ;

Suman, VJ ;

Geyer, CE ;

Davidson, NE ;

Tan-Chiu, E ;

Martino, S ;

Paik, S ;

Kaufman, PA ;

Swain, SM ;

Pisansky, TM ;

Fehrenbacher, L ;

Kutteh, LA ;

Vogel, VG ;

Visscher, DW ;

Yothers, G ;

Jenkins, RB ;

Brown, AM ;

Dakhil, SR ;

Mamounas, EP ;

Lingle, WL ;

Klein, PM ;

Ingle, JN ;

Wolmark, N .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16) :1673-1684

[9] Classical peer review: an empty gun [J].

Smith, Richard .

BREAST CANCER RESEARCH, 2010, 12

[10] Compendium of Unpublished Phase III Trials in Oncology: Characteristics and Impact on Clinical Practice [J].

Tam, Vincent C. ;

Tannock, Ian F. ;

Massey, Christine ;

Rauw, Jennifer ;

Krzyzanowska, Monika K. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (23) :3133-3139

← 1 →